Bioengineering, Journal Year: 2024, Volume and Issue: 12(1), P. 6 - 6
Published: Dec. 25, 2024
Glaucoma, a progressive and multifactorial optic neurodegenerative disease, still poses significant challenges in both diagnosis management remains perpetual enigma [...].
Language: Английский
Molecular Therapy, Journal Year: 2025, Volume and Issue: 33(3), P. 1246 - 1263
Published: Jan. 18, 2025
Language: Английский
Citations
1
Progress in Retinal and Eye Research, Journal Year: 2024, Volume and Issue: 102, P. 101288 - 101288
Published: Aug. 2, 2024
Language: Английский
Citations
6
Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1325 - 1325
Published: Oct. 12, 2024
Eye disorders affect a substantial portion of the global population, yet availability efficacious ophthalmic drug products remains limited. This can be partly ascribed to number factors: (1) inadequate understanding physiological barriers, treatment strategies, and polymer properties, delivery systems; (2) challenges in effectively delivering drugs anterior posterior segments eye due anatomical constraints; (3) manufacturing regulatory hurdles ocular product development. The present review discusses innovative treatments, encompassing implants, liposomes, nanoparticles, nanomicelles, microparticles, iontophoresis, situ gels, contact lenses, microneedles, hydrogels, bispecific antibodies, gene strategies. Furthermore, this also introduces advanced technologies such as 3D printing hot-melt extrusion (HME), aimed at improving bioavailability, reducing therapeutic dosages side effects, facilitating design personalized dosage forms, well enhancing patient compliance. comprehensive lastly offers insights into digital healthcare, market trends, industry perspectives pertaining
Language: Английский
Citations
5
Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 365 - 365
Published: Feb. 5, 2025
Eye diseases can significantly affect the quality of life patients due to decreased visual acuity. Although modern ophthalmological diagnostic methods exist, some system are asymptomatic in early stages. Most seek advice from an ophthalmologist as a result rapidly progressive manifestation symptoms. A number inherited and acquired eye have only supportive treatment without eliminating etiologic factor. promising solution this problem may be gene therapy, which has proven efficacy safety shown clinical studies. By directly altering or replacing defective genes, therapeutic approach will stop well reverse progression diseases. This review examines concept therapy its application field ocular pathologies, emphasizing most recent scientific advances their potential impacts on function status.
Language: Английский
Citations
0
Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 1021 - 1037
Published: Feb. 1, 2024
Introduction: Glaucoma is the most common optic neuropathy and leading cause of irreversible blindness worldwide, which affects 3.54% population aged 40– 80 years. Despite numerous published studies, some aspects glaucoma pathogenesis, serum biomarkers, their potential link with other diseases remain unclear. Recent articles have proposed that autoimmune, oxidative stress inflammation may be involved in pathogenesis glaucoma. Methods: We investigated expression 92 inflammatory neurotrophic factors patients. The study group consisted 26 patients 192 healthy subjects based on digital fundography. Results: Patients had significantly lower IL-2Rβ, TWEAK, CX3CL1, CD6, CD5, LAP TGF-beta1, LIF-R, TRAIL, NT-3, CCL23 higher IL-22Rα 1. Conclusion: Our results indicate tend to levels neuroprotective proteins neuroinflammatory proteins, similar those observed psychiatric, neurodegenerative autoimmune diseases, indicating a between these conditions pathogenesis. Keywords: glaucoma, inflammation, neurodegeneration, proteomics, Olink
Language: Английский
Citations
3
Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18
Published: March 18, 2024
Glaucoma is a complex and progressive disease that primarily affects the optic nerve axons, leading to irreversible vision loss. Although exact molecular mechanisms underlying glaucoma pathogenesis are not fully understood, it believed except increased intraocular pressure, combination of genetic environmental factors play role in development disease. Animal models have been widely used study glaucoma, allowing researchers better understand test potential treatments. Several pathways implicated including oxidative stress, inflammation, excitotoxic-induced neurodegeneration. This review summarizes most important knowledge about involved development. much research has done this disease, there still be learned develop effective treatments prevent loss those affected by glaucoma.
Language: Английский
Citations
3
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8876 - 8876
Published: Aug. 15, 2024
Glaucoma, a leading cause of blindness, is multifactorial condition that leads to progressive loss retinal ganglion cells (RGCs) and vision. Therapeutic interventions based on reducing ocular hypertension are not always successful. Emerging features glaucoma include mitochondrial dysfunction oxidative stress. In the current study, NDI1-based gene therapy, which improves function reduces reactive oxygen species, was delivered intraocularly via an adeno-associated viral vector (AAV). This AAV-NDI1 therapy protected RGCs from cell death in treated (1552.4 ± 994.0 RGCs/mm2) versus control eyes (1184.4 978.4 RGCs/mm2, p < 0.05) aged DBA/2J mice, murine model glaucoma. The photonegative responses (PhNRs) were also improved (6.4 3.3 µV) (5.0 3.1 µV, these mice. provided benefits glaucomatous human lamina cribrosa (LC) by significantly increasing basal maximal consumption rates ATP production cells. Similarly, NDI1 H2O2-insulted primary porcine LC study highlights potential utility therapies improving treatment
Language: Английский
Citations
3
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(14), P. 4224 - 4224
Published: July 19, 2024
With a common aim of restoring physiological function defective cells, optogenetics and targeted gene therapies have shown great clinical potential novelty in the branch personalized medicine inherited retinal diseases (IRDs). The basis aims to bypass photoreceptors by introducing opsins with light-sensing capabilities. In contrast, therapies, such as methods based on CRISPR-Cas9 RNA interference noncoding RNAs (i.e., microRNA, small interfering RNA, short hairpin RNA), consists inducing normal or protein expression into affected cells. Having partially leveraged challenges limiting their prompt introduction practice engineering, cell tissue delivery capabilities), it is crucial deepen fields knowledge applied therapy. this in-depth novel literature review explain fundamentals applications while providing decision-making arguments for ophthalmologists. First, we biomolecular principles engineering steps involved mentioned above bringing focus specific vectors molecules signalization. importance vector choice are discussed. Second, summarize ongoing trials most recent discoveries IRDs. Finally, then discuss limits current each We provide first time scientific-based explanations clinicians justify specificity therapy one disease, which can help improve tasks.
Language: Английский
Citations
3
Vision Research, Journal Year: 2024, Volume and Issue: 225, P. 108502 - 108502
Published: Oct. 18, 2024
Language: Английский
Citations
2
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 21, 2024
Corneal transplantation is a critical surgical procedure aimed at restoring vision in patients with corneal blindness or severe damage. This review focuses on secondary glaucoma, significant postoperative complication, the primary objective of providing comprehensive analysis its pathophysiology, risk factors, diagnostic challenges, and therapeutic approaches. Unlike other reviews, this work emphasizes interplay between inflammatory responses, corticosteroid use, structural changes eye that lead to elevated intraocular pressure (IOP) after transplantation. A literature was conducted, including studies postcorneal highlight both clinical outcomes efficacy current management strategies. Key findings indicate medical treatments, such as prostaglandin analogs beta-blockers, are effective for IOP control early stages, while interventions, like trabeculectomy, often necessary more advanced cases. Diagnostic difficulty accurate measurement posttransplant, underscored, along importance imaging techniques detection optic nerve The pathophysiology glaucoma involves complex interaction postsurgical inflammation, steroid-induced complications, anatomical hinder aqueous humor outflow. Diagnosis requires combination tonometry, gonioscopy, technologies. Management strategies range from pharmacological treatments options, focus balancing minimizing risks graft survival. Clinically, these need proactive tailored transplant preserve function long-term visual outcomes. Future research should improving accuracy, developing less invasive techniques, exploring personalized medicine approaches, genetic profiling targeted therapies.
Language: Английский
Citations
1